Royal Bank of Canada trimmed its holdings in Exactech, Inc. (NASDAQ:EXAC) by 10.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,477 shares of the medical equipment provider’s stock after selling 4,227 shares during the quarter. Royal Bank of Canada owned 0.25% of Exactech worth $1,086,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently bought and sold shares of EXAC. Gamco Investors INC. ET AL acquired a new stake in Exactech during the 2nd quarter worth about $18,463,000. FMR LLC raised its holdings in Exactech by 51.6% during the 2nd quarter. FMR LLC now owns 251,876 shares of the medical equipment provider’s stock worth $7,506,000 after buying an additional 85,709 shares during the period. Thomson Horstmann & Bryant Inc. raised its holdings in Exactech by 42.2% during the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 274,062 shares of the medical equipment provider’s stock worth $8,167,000 after buying an additional 81,291 shares during the period. Algert Global LLC acquired a new stake in Exactech during the 2nd quarter worth about $1,454,000. Finally, Dimensional Fund Advisors LP raised its holdings in Exactech by 6.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 827,761 shares of the medical equipment provider’s stock worth $24,668,000 after buying an additional 47,315 shares during the period. Hedge funds and other institutional investors own 65.04% of the company’s stock.
In other news, Director Fern Watts sold 1,013 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total value of $29,417.52. Following the sale, the director now directly owns 4,727 shares of the company’s stock, valued at approximately $137,272.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 28.30% of the company’s stock.
Shares of Exactech, Inc. (NASDAQ:EXAC) opened at $42.20 on Friday. The company has a quick ratio of 2.18, a current ratio of 4.15 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $610.25 million, a PE ratio of 34.71, a PEG ratio of 3.60 and a beta of 1.04.
Exactech (NASDAQ:EXAC) last issued its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). Exactech had a return on equity of 7.29% and a net margin of 0.18%. The company had revenue of $61.40 million during the quarter, compared to the consensus estimate of $61.78 million. equities research analysts forecast that Exactech, Inc. will post 1.29 earnings per share for the current year.
EXAC has been the topic of several recent analyst reports. Gabelli restated a “buy” rating on shares of Exactech in a report on Monday, July 31st. Robert W. Baird set a $34.00 price objective on Exactech and gave the stock a “buy” rating in a report on Sunday, October 15th. BidaskClub upgraded Exactech from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Sidoti downgraded Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Finally, Zacks Investment Research downgraded Exactech from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $42.00.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
What are top analysts saying about Exactech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech Inc. and related companies.